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Glutathione deficiency is an early biochemical feature that occurs
during apoptotic neuronal death associated with certain neurolog-
ical disorders such as Parkinson disease. However, whether specific
targeting of glutathione biosynthesis in neurons is sufficient to trig-
ger neurodegeneration remains undetermined. To address this
issue, we used a vector-based small hairpin RNA (shRNA) strategy
to knock down each subunit of glutamate-cysteine ligase (GCL;
-glutamylcysteine synthetase), the heterodimeric enzyme that cat-
alyzes the rate-limiting step of glutathione biosynthesis. Independ-
ent targeting of the catalytic and modulatory subunits by shRNA
caused disruption of GCL as assessed by Northern and Western
blotting, enzymeactivity, and glutathione concentrations. Silencing
each subunit in primary cortical neurons spontaneously elicited
time-dependent apoptotic death, an effect that was synergistic with
glutamate or nitric oxide treatment. Moreover, neuronal apoptosis
by GCL knockdown was rescued by expressing the corresponding
subunit full-length cDNA carrying silent mutations within the
shRNA target cDNA sequence and by incubating neurons with
-glutamylcysteine or glutathione ethyl ester. In contrast, supply-
ing glutathione precursors to neurons from co-cultured astrocytes
did not prevent the apoptotic death triggered by GCL knockdown.
Finally, overexpressing the catalytic (but notmodulatory) GCL sub-
unit full-length cDNA increased enzyme activity and glutathione
concentrations, yielding neurons more resistant to glutamate- or
nitric oxide-mediated apoptosis. Thus, specific and independent
disruption of each subunit of GCL in neurons can be said to cause
a primary decrease in glutathione that is sufficient to promote
neurodegeneration.
Glutathione is a critical non-protein thiol involved in antioxidant
defense (1) and whose loss has been associated with neurodegeneration
(2). Thus, glutathione deficiency is the earliest known biochemical indi-
cator of nigrostriatal degeneration in Parkinson disease (3), an observa-
tion suggesting that oxidative stress may be a cause of the apoptotic
neuronal death associated with neurodegenerative processes and aging
(2, 4–6). Unfortunately, to date, no unambiguous demonstration that
the specific loss of glutathione is sufficient to trigger neurodegeneration
has been reported.
Glutathione is a tripeptide (-glutamylcysteinylglycine) synthesized
by two consecutive ATP-dependent reactions. Glutamate-cysteine
ligase (GCL4; EC 6.3.2.2, -glutamylcysteine synthetase) catalyzes the
first and rate-limiting step, forming -glutamylcysteine from glutamate
and cysteine (7). This is followed by the glutathione synthetase (EC
6.3.2.3)-catalyzed reaction, which binds glycine to -glutamylcysteine,
forming glutathione (8). GCL is a heterodimeric enzyme composed of a
catalytic subunit (heavy; 73 kDa) (9) and a modulatory subunit (light;
27.7 kDa) (10). Studies performed with purified GCL suggest that the
active site resides at the catalytic subunit, whereas the modulatory sub-
unit increases the affinity of the catalytic subunit for glutamate and
decreases the sensitivity to feedback inhibition by glutathione (9).
Homozygous embryonic mice with targeted disruption of the catalytic
GCL subunit (Cat) have been obtained, but they are not viable beyond
the 8th gestational day (11, 12). On the other hand, initial characteriza-
tions of homozygous knockout mice for the modulatory GCL subunit
(Mod) revealed that they are viable and fertile, hence providing an inter-
esting model for the in vivo study of mild and chronic glutathione defi-
ciency (13). However, the biochemical, molecular, and cellular pheno-
types of the brains of these mice have not yet been investigated. Thus,
the specific contribution of eachGCL subunit to the survival of neurons
is still elusive.
To disrupt cellular glutathione biosynthesis, a widely used pharma-
cological approach has long been the administration of L-buthionine
sulfoximine, a competitive inhibitor of GCL activity that presumably
interferes exclusively with the catalytic subunit (14). However, L-buthi-
onine sulfoximine also inhibits the glutamyl amino acid transporter (15)
and hence may affect other unknown biochemical pathways. An ele-
gantly designed inducible vector-based full-length antisense cDNA
approach has been described to induce a concomitant depletion of both
GCL subunits in PC12 cells (16, 17). Such an approach requires cell lines
constitutively expressing the tetracycline repressor, but is unsuitable for
primary cells such as cortical neurons. In addition, this system does not
afford any information about the impact of each GCL subunit on gluta-
thione biosynthesis.
With the aim of elucidating the specific contribution of each GCL
subunit to glutathione biosynthesis and neuronal survival by overcom-
ing these potential drawbacks, in this work, we used the small interfer-
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ing RNA (siRNA) strategy. This system, which has been proven to be
more specific and efficient than the full-length antisense cDNA strategy
(18), allowed us to identify siRNAs (delivered from a plasmid expression
vector) that triggered highly specific and efficient GCL subunit protein
disruption and the inhibition of enzyme activity, leading to glutathione
depletion and neuronal death. We believe that these results unambigu-
ously confirm that bothGCL subunits are essential for glutathione bio-
synthesis and neuronal survival.
MATERIALS AND METHODS
Reagents—Dulbecco’s modified Eagle’s medium (DMEM), poly-D-
lysine, horse serum, cytosine arabinoside, and glutathione ethyl ester
were obtained from Sigma. DMEMwas always supplemented with pen-
icillin (100 units/ml), streptomycin (100 g/ml), and amphotericin B
(0.25g/ml) (Sigma). Fetal calf serum (FCS) was purchased fromRoche
Diagnostics (Heidelberg, Germany). The apoptosis assay kit was pur-
chased from BD Biosciences. Lipofectamine 2000 was purchased
from Invitrogen (Groningen, The Netherlands). -Glutamylcysteine
was purchased from Bachem (Weil am Rhein, Germany). Other sub-
strates, enzymes, and coenzymes were purchased from Sigma, Roche
Diagnostics, Merck (Darmstadt, Germany), and Promega Biotech
(Madrid, Spain). Plastic tissue culture flasks were purchased fromNunc
(Roskilde, Denmark).
Design of Small Hairpin RNAs (shRNAs) for GCL—GCL subunit
knockdown was achieved by RNA interference (RNAi) using a vector-
based shRNA approach (19). Five shRNA target cDNA sequences were
selected for each GCL subunit according to a previously reported ratio-
nal design protocol (see TABLE ONE) (20). As a control, we used the
firefly luciferase-targeted oligonucleotide 5-CTGACGCGGAATAC-
TTCGA-3 as reported previously (21). All sequences were BLAST-
confirmed for specificity. Synthetic forward and reverse 64-nucleotide
oligonucleotides (Isogen Life Science, Maarsen, The Netherlands) were
designed, annealed, and inserted into the BglII/HindIII sites of the
pSUPER-neo/GFP vector (OligoEngine, Seattle, WA) following the
manufacturer’s instructions. These constructions express 19-bp 9-nu-
cleotide stem-loop shRNAs targeted against GCL, the catalytic (Cat
shRNA) or modulatory (Mod shRNA) GCL subunit, or luciferase (con-
trol shRNA) mRNAs. The concomitant expression of green fluorescent
protein (GFP) from this vector allowed the identification of transfected
cells by fluorescence microscopy and flow cytometry.
Plasmid Constructions—The Cat full-length cDNA (2023 bp; Gen-
BankTM accession number NM_012815) was obtained by ligating, at
position 1117 of the cDNA (with an unique ClaI site), two cDNA frag-
ments of 1 kb each, which were independently obtained by reverse
transcription-PCR of total RNA from rat astrocytes as template. The
oligonucleotides used were 5-CCGGAATTCGCCATGGGGCT-
GCTG-3 (sense) and 5-TGCCAGAAGGTGATCGATGCCTT-3
(antisense) for the 5-end fragment and 5-AAGGCATCGATCACCT-
TCTGGCA-3 (sense) and 5-CCGGAATTCCAACTGGAACACTG-
TAG-3 (antisense) for the 3-end fragment (with EcoRI sites under-
lined). The Mod full-length cDNA (905 bp; GenBankTM accession
number NM_017305) was obtained by reverse transcription-PCR of
total RNA from rat astrocytes as template. The oligonucleotides used
were 5-CGCGGATCCTCCCCTCGGGCGGCAGCT-3 (sense) and
5-CGCGGATCCTAAATACAAGGCCCCTGAG-3 (antisense)
(with BamHI sites underlined). The reverse transcription-PCR condi-
tions were as follows: 50 min at 48 °C for reverse transcription; 3 min at
94 °C; 40 cycles of 1 min at 94 °C, 1 min at 53 °C for Cat and at 55 °C for
Mod, and 2.5 min for Cat and 1 min for Mod at 68 °C; and a final
extension for 10 min at 68 °C. The cDNA products were purified,
digested, and subcloned into the corresponding EcoRI or BamHI site of
the pIRES2-EGFP mammalian expression vector (Invitrogen) (pIRES-
Cat or pIRES-Mod) and sequenced. The concomitant expression of
GFP from this vector allowed the identification of transfected cells by
fluorescence microscopy and flow cytometry.
Site-directedMutagenesis—To assess whether the shRNA procedure
was specific, wild-type (Cat or Mod) or mutant (Cat-mut or Mod-mut)
forms of the rat catalytic or modulatory GCL subunit full-length cDNA
were used. Cat-mut and Mod-mut were obtained by PCR site-directed
mutagenesis using pIRES-Cat and pIRES-Mod, respectively, as tem-
plate, followed by DpnI digestion (QuikChange XL, Stratagene). The
selected PCR forward and reverse 50-nt oligonucleotides carried silent
third codon base point mutations within the rat cDNA-corresponding
Cat-d and Mod-c shRNA target sequences (5-GAAAGAAGC-
CACGTCAGTT-3 for Cat and 5-GGCATCGCCACCTATCGAG-3
for Mod; with mutated nucleotides underlined).
Antibodies against the Catalytic and Modulatory GCL Subunits—
Polyclonal antibodies against the catalytic and modulatory subunits of rat
GCL were obtained by rabbit immunization with synthetic peptides
(Mimotopes Pty. Ltd., Clayton, Victoria, Australia). The peptides were
16QRHADHVRRHGILQ29 for the catalytic subunit and 229EALQESIP-
DIEAQE242 for themodulatory subunit. Rabbitswere immunizedwith 100
ng of the peptides coupled to keyhole limpet hemocyanin according to the
procedure described by Sambrook et al. (22). To improve the detection of
the proteins, antibodieswere purified from the antisera by affinity chroma-
tographyusingcolumnsofcyanogenbromide-activatedSepharosecoupled
to the peptides.
Neurons in Primary Culture—Cerebral cortex neurons in primary
culture were prepared from fetalWistar rats at 16 days of gestation (23).
Dissociated cell suspensions were plated at a density of 2.5  105 cells/
cm2 in 6- or 12-well plates previously coated with poly-D-lysine (15
g/ml) in DMEM supplemented with 10% FCS. Cells were incubated at
37 °C in a humidified atmosphere containing 5% CO2 and 95% air. For-
ty-eight hours after plating, the medium was replaced with DMEM
supplemented with 5% horse serum, 20 mM D-glucose, and 10 M cyto-
sine arabinoside to prevent non-neuronal proliferation. Neurons were
transfected on day 5, when 99% of the cells were microtubule-associ-
ated protein-2-positive.
Astrocytes in Primary Culture—Astrocytes in primary culture were
prepared from the forebrains of neonatal rats (24 h old). Cell suspen-
sions were seeded at a density of 1.2 105 cells/cm2 in 175-cm2 flasks in
culture medium (DMEM supplemented with 10% FCS). Cells were
incubated at 37 °C under a humidified 5% CO2-containing atmosphere
for 12 days, after which time 85% of the cells were astrocytes and the
remaining proportion was microglia and progenitor cells as assessed by
immunocytochemistry (23).
Neuron-Astrocyte Co-culture—Twenty-four h before the co-culture
experiments, astrocytes were trypsinized and reseeded at 1.2  105
cells/cm2 inMillicell-PCF cell culture inserts (4.2 cm2 of effectivemem-
brane area, 0.4-mmembrane pore size;Millipore Corp. Bedford,MA).
To co-incubate astrocytes with neurons, astrocytes previously seeded in
the cell culture inserts were placed on top of the neuronal cultures and
bathed in DMEM (24). After 24 h of incubation, the inserts were
removed, and the neurons were washed and used for the determination
of either glutathione concentrations or apoptotic cell death.When nec-
essary, neurons were transfected with the appropriate plasmid vectors
6 h before co-incubation.
Human Embryonic Kidney 293T (HEK293T) Cells—HEK293T cells
were maintained in DMEM supplemented with 10% (v/v) FCS. Cells
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were reseeded at 105 cells/cm2 1 day before transfections, after which
FCS was reduced to 0.5% (v/v).
Cell Treatments—Cell transfections were performed with pSUPER-
neo/GFP- or pIRES2-EGFP-derived plasmid constructions using Lipo-
fectamine 2000 following themanufacturer’s instructions. After 6 h, the
medium was removed, and cells were further incubated for the indi-
cated time periods in the presence of culture medium. To activate glu-
tamate receptors, 24 h after transfections, neurons were incubated with
100Mglutamate (plus 10Mglycine) in bufferedHanks’ solution (5.26
mM KCl, 0.43 mM KH2H2PO4, 132.4 mM NaCl, 4.09 mM NaHCO3, 0.33
mMNa2HPO4, 20mM glucose, 2mMCaCl2, and 20mMHEPES, pH 7.4).
After 5 min, when glutamate receptors were activated (25), neurons
were washed and further incubated in culturemedium for the indicated
time periods. To expose the transfected cells to nitric oxide, they were
incubated in buffered Hanks’ solution containing (Z)-1-[2-aminoethyl-
N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA/NO;
Alexis Biochemicals) at 0.5 mM, a concentration seen to release contin-
uously 1.4 M nitric oxide at 37 °C, as measured using a nitric oxide-
sensitive electrode (World Precision Instruments), for the indicated
time periods. To ensure immediate exposure of the cells to nitric oxide,
all DETA/NO-containing solutions were always preincubated in buff-
ered Hanks’ solution at 37 °C for 20 min before addition to the cells
(23, 26).
Northern Blotting—Total RNA samples were purified (GenElute
mammalian total RNAminiprep kit, Sigma) and electrophoresed (10g
of RNA/line) on a formaldehyde-containing 1% (w/v) agarose gel. After
transfer to a GeneScreen Plus membrane (PerkinElmer Life Sciences)
and cross-linking by ultraviolet irradiation,membraneswere hybridized
for 18 h at 65 °C in the presence of the appropriate random-primed
[-32P]dCTP-radiolabeled cDNAprobe (AmershamBiosciences, Buck-
inghamshire, UK) and exposed to Kodak XAR-5 film. We used the
cDNA probes against rat Cat or Mod. A 0.7-kb cDNA fragment of the
rat cyclophilin gene (generously donated byDr. DionisioMartı́n-Zanca,
University of Salamanca) was used as a control of the amount of total
RNA loaded onto each lane. Autoradiograms were scanned and quan-
tified using NIH Image software. The scanned mRNA autoradiograms
were expressed as a ratio versus cyclophilin mRNA.
Western Blotting—Cells were lysed for 20 min at 4 °C in buffer con-
taining 1%Nonidet P-40, 5mMEDTA, 2mMEGTA, 20mMTris, pH 8.0,
137 mM NaCl, 10% glycerol, 100 M phenylmethylsulfonyl fluoride, 50
g/ml antipapain, 50 g/ml pepstatin, 50 g/ml amastatin, 50 g/ml
leupeptin, 50 g/ml bestatin, 1 mM o-vanadate, 50 mM NaF, and 50
g/ml soybean trypsin inhibitor. Extracts were centrifuged at 13,000 
g for 20min at 4 °C, and aliquots containing 100g of protein from each
sample, as determined extemporarily with the BCATM protein assay kit
(Pierce) using albumin as a standard and the BenchMarkTM prestained
protein ladder (Invitrogen), were subjected to SDS-PAGE on an 8%
(catalytic subunit) or 12% (modulatory subunit) acrylamide gel (Mini-
PROTEAN, Bio-Rad). The resolved proteins were transferred electro-
phoretically to nitrocellulose membranes (Hybond-ECL, Amersham
Bioscience EuropeGmbH, Barcelona, Spain).Membranes were blocked
with 5% (w/v) low-fat milk in 20mMTris, 500 mMNaCl, and 0.1% (w/v)
Tween 20, pH 7.5, for 1 h. GCL immunoblotting was performed using
the anti-catalytic and anti-modulatory subunit antibodies that we raised
(see above) at dilutions of 1:20 and 1:5, respectively. Anti-phosphofruc-
tokinase-1 antibody (1:500 dilution) was used as a loading control (23).
Membranes were incubated with horseradish peroxidase-conjugated
goat anti-rabbit IgG (1:10,000 dilution; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) and immediately incubated with SuperSignal West
Dura (Pierce) for 5 min before exposure to Kodak XAR-5 film for 1–3
min. Autoradiograms were scanned, quantified using NIH Image soft-
ware, and expressed as a ratio versus phosphofructokinase-1.
GCL Activity—For the determination of GCL activity, we followed
the method of Gegg et al. (27). In brief, 24 h after transfections, cells
were washed, harvested by mild trypsinization, pelleted, and resus-
pended in isolation medium (320 mM sucrose, 10 mM Tris, and 1 mM
EDTA, pH 7.4). Cell suspensions were freeze-thawed three times, and
the lysates were filtered through 10-kDa molecular mass cutoff devices
(Amicon, Inc., andMillipore Corp.) at 12,000 g for 15min at 4 °C. The
retained protein fraction was immediately assayed for GCL activity in
0.1 M Tris-HCl containing 0.15mMKCl, 20mMMgCl2, 2 mM EDTA, 10
mM ATP, 10 mM L-cysteine, 40 mM L-glutamate, and 220 M acivicin,
pH 8.2, at 37 °C for 20 min. The reaction was stopped by addition of
ice-cold orthophosphoric acid (15 mM), and the reaction product was
immediately used for -glutamylcysteine determination by high pres-
sure liquid chromatography (Beckman Instruments) with electrochem-
ical detection (ESA Biosciences, Inc., Chelmsford, MA) using a Tech-
sphere ODS column (4.6  250 mm, 5-m particle size) and 15 mM
orthophosphoric acid as the mobile phase (27). An external standard of
-glutamylcysteine (2.5–10 M) was used for the calculations. Prelimi-
nary experiments showed that, under these conditions, -glutamylcys-
teine synthesis was linear with the incubation time at least up to 20min.
Glutathione Concentrations—Cells were washed with ice-cold phos-
phate-buffered saline and immediately scraped off the plastic with 1%
(w/v) sulfosalicylic acid. Cell lysates were centrifuged at 13,000 g for 5
min at 4 °C, and the supernatants were used for the determination of
total glutathione concentrations (GSH  2 GSSG) on the same day
using GSSG as a standard (0–50 M) as described previously (28–30).
Flow Cytometric Analysis of Apoptotic Cell Death—Allophycocya-
nin-conjugated annexin V and 7-aminoactinomycin D (7-AAD) (BD
Biosciences) were used to quantitatively determine the percentage of
apoptotic cells by flow cytometry. Cells were stainedwith allophycocya-
nin-conjugated annexin V and 7-AAD following the manufacturer’s
instructions and analyzed on a FACSCalibur flow cytometer (15-milli-
watt argon ion laser tuned at 488 nm; CellQuest software, BD Bio-
sciences). BothGFP-positive andGFP-negative cells were analyzed sep-
arately, and the allophycocyanin-conjugated annexin V-stained cells
that were 7-AAD-negative were considered apoptotic (23).
Statistical Analysis—Measurements from individual cultures were
always performed in triplicate. The results are expressed as themeans
S.E. for three different culture preparations. Statistical analysis of the
results was performed by one-way analysis of variance, followed by the
least significant difference multiple range test. In all cases, p  0.05 was
considered significant.
RESULTS
Design, Expression, and Efficacy of shRNAs against the Catalytic and
Modulatory GCL Subunits—To promote the specific silencing of GCL,
five 19-nucleotide sequences were designed for each subunit according
to a recently reported rational criterion for RNAi design for siRNA (20).
These sequences were selected using the human GCL cDNA template
within regions that were best conserved in rat (GenBankTM accession
numbers NM_012815 (Cat) and NM_017305 (Mod)) and mouse
(accession numbers NM_010295 (Cat) and NM_008129 (Mod)). Only
those sequences that fulfilled at least six criteria were selected; these are
shown in TABLE ONE. These sequences were subcloned into a GFP
cDNA-coexpressing pSUPER-neo/GFP mammalian expression vector
(19) to promote the expression of the corresponding shRNAmolecules.
The use of such an expression vector allows the specific and independ-
ent siRNA-mediated silencing of GCL subunits via the Dicer-triggered
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38994 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280 • NUMBER 47 • NOVEMBER 25, 2005
cleavage of shRNAs (18). To investigate the efficacy of the shRNA pro-
cedure, we obtained antibodies raised against the rat catalytic andmod-
ulatory GCL subunits. These antibodies proved to be highly specific, as
revealed by the appearance of a single band of the expected size in rat
kidney extracts by Western blotting (Fig. 1A). Because the endogenous
GCL (Cat and Mod) protein levels were too low to be detectable by
Western blotting in cultured cells (data not shown), we estimated the
efficacy of the selected shRNAs by assaying their ability to interfere with
the respective expressed proteins. To accomplish this, we first obtained
the full-length cDNAs for both the catalytic and modulatory GCL sub-
units by reverse transcription-PCR, and these were subcloned into the
GFP cDNA-coexpressing pIRES mammalian expression vector. The
FIGURE 1. Expression and efficacy of shRNAs
against the catalytic and modulatory GCL sub-
units. A, Western blotting of rat kidney extracts
revealed single bands at the appropriate molecu-
lar masses using antibodies raised against the cat-
alytic (-Cat) and modulatory (-Mod) GCL sub-
units. IB, immunoblot. B, transfections of HEK293T
cells with pIRES-derived plasmids encoding Cat
and Mod cDNAs (pIRES-Cat and pIRES-Mod,
respectively) afforded the corresponding bands
by Western blotting. C, coexpression in HEK293T
cells of pIRES-Cat with five different shRNAs tar-
geted against the catalytic GCL subunit (upper
panels) or pIRES-Mod with five different shRNAs
targeted against the modulatory GCL subunit
(lower panels) revealed different degrees of effi-
cacy of the selected shRNAs in silencing the
expression of the corresponding subunits com-
pared with control luciferase (Luc) shRNA transfec-
tions. The shRNAs were expressed using the pSU-
PER-neo/GFP mammalian expression vector. In
light of the different efficiencies, Cat-d and Mod-c
shRNA sequences were used in ensuing experi-
ments. Phosphofructokinase-1 (PFK-1) was used a
loading control. The bands were scanned and ana-
lyzed, and the Cat/phosphofructokinase-1 and
Mod/phosphofructokinase-1 ratios (indicated
under the corresponding condition) were used to
estimate the efficiencies of the different shRNAs.
D, transfection of HEK293T cells with Cat-d and
Mod-c shRNAs decreased the abundance of the
corresponding endogenous mRNAs as assessed
by Northern blotting. Cyclophilin (Cic) was used as
loading control. E, transfection of HEK293T cells
with shRNA against each GCL subunit did not
affect the expression of the other subunit.
TABLE ONE
Oligonucleotides (19 nucleotides) selected for siRNA against Homo sapiens GCL
ORF, open reading frame.
Name siRNA target sequence Start
Criteriona
1 2 3 4 5 6 7 8
Catalytic subunit (accession no. NM_001498; 3717 bp; ORF region 389–2302)
Cat-a TCAGTACCTTAACAAGAAA 945        
Cat-b CTAAGCCGGATCATATTTA 1080        
Cat-c CCAGATACCTTTATGATCA 1173        
Cat-d GAAGGAGGCTACTTCTATA 772        
Cat-e GAGTGATCCTTTCCTACAA 1737        
Modulatory subunit (accession no. NM_002061; 1610 bp; ORF region 254–1078)
Mod-a ACAGCGAGGAGCTTCATGA 369        
Mod-b TTCAGTCCTTGGAGTTGCA 595        
Mod-c TGCTTCACCTCCTATTGAA 634        
Mod-d ACCAAATAGTAACCAAGTT 799        
Mod-e CCAAATAGTAACCAAGTTA 800        
a Satisfies () or not () the corresponding criteria reported previously (20) for the rational design of siRNA for RNA interference.
Neuronal Glutathione shRNA Knockdown
NOVEMBER 25, 2005 • VOLUME 280 • NUMBER 47 JOURNAL OF BIOLOGICAL CHEMISTRY 38995
expression of these plasmids in HEK293T cells afforded proteins with
the expected corresponding catalytic or modulatory GCL subunit sizes
(Fig. 2B). The expression of five different shRNAs for each GCL subunit
in HEK293T cells differentially disrupted the expression of the corre-
sponding subunits (Fig. 1C) comparedwith control transfections, which
were performed with shRNA against luciferase. In light of these results,
we selected Cat-d and Mod-c shRNAs (Fig. 1C and TABLE ONE)
because they were among themost effective shRNAs. The selected shR-
NAs (Cat-d and Mod-c) were then expressed in HEK293T cells, and
their efficacy was assayed further byNorthern blotting. As shown in Fig.
1D, Cat-d and Mod-c shRNAs efficiently decreased the endogenous
levels of the catalytic and modulatory GCL subunit mRNAs, respec-
tively. To corroborate further the specificity of this approach, we inves-
tigatedwhether the shRNA against each subunit affected the expression
of the other subunit. As shown in Fig. 1E, Cat-d shRNAdid not affect the
protein levels of the modulatory subunit, and Mod-c shRNA did not
affect the protein levels of the catalytic subunit. In view of the efficacy
and specificity of the selected shRNAs, all remaining experiments were
performed using Cat-d and Mod-c shRNAs.
Both GCL Subunits Are Essential for Glutathione Biosynthesis in
Intact Cells—The relative contribution of eachGCL subunit to support-
ing GCL activity and glutathione concentrations in intact cells is still a
controversial issue, with studies reporting either decreases (31) or no
changes (32) in glutathione concentrations upon disruption of themod-
ulatory GCL subunit using ribozyme or full-length antisense mRNA
expression in pancreatic and hepatoblastoma cell cultures, respectively.
Conversely, glutathione concentrations have been reported to be both
maintained upon catalytic GCL subunit overexpression (10) and
increased after catalytic or modulatory GCL subunit overexpression
(33–35). Because these discrepancies do not allow the relative impact of
each GCL subunit on neuronal survival to be clarified, we first investi-
gated whether the independent disruption of GCL subunits by siRNA
altered the enzyme activity and glutathione concentrations. To perform
this, the shRNA targeted against the catalytic (Cat-d shRNA) or modu-
latory (Mod-c shRNA) GCL subunit was expressed in HEK293T cells,
and enzyme activity and glutathione concentrations were measured in
the cell extracts. Disruption of the catalytic subunit inhibitedGCL activ-
ity by55%, whereas disruption of themodulatory subunit resulted in a
modest but significant 25% decrease in GCL activity (Fig. 2A, left
panel). Likewise, total glutathione concentrations time-dependently
decreased after transfections with Cat or Mod shRNA (Fig. 2A, right
panel). Conversely, overexpression of the catalytic GCL subunit
(pIRES-Cat) dramatically increased GCL activity (by 500-fold). In
contrast, overexpression of the modulatory GCL subunit (pIRES-Mod)
did not affect GCL activity (Fig. 2B, left panel). Coexpression of both the
catalytic and modulatory subunits did not result in further increases in
GCL activity compared with overexpression of the catalytic subunit
alone (Fig. 2B, left panel). Likewise, total glutathione concentrations
increased (by 1.4-fold) after overexpression of the catalytic GCL sub-
unit, but were unmodified after overexpression of the modulatory sub-
unit (Fig. 2B, right panel). Interestingly, the concomitant overexpression
of bothGCL subunits synergistically increased (by2-fold) glutathione
concentrations compared with the overexpression of the catalytic sub-
unit alone (Fig. 2B, right panel).
Both GCL Subunits Are Essential for the Survival of Primary Neurons—
Neurons are especially vulnerable to oxidative and nitrosative stress
(36–38), and the pharmacological inhibition of GCL activity with L-bu-
thionine sulfoximine elicits apoptotic neuronal death (39). However, so
far, there is no evidence indicating the relative contribution of eachGCL
subunit to neuronal survival and susceptibility to oxidative and nitrosa-
tive stress. Thus, we next studied whether the disruption of GCL activ-
ity, by specifically interfering with each GCL subunit, and the subse-
quent glutathione loss might be sufficient to trigger neurodegeneration.
To address this issue, we transfected rat cortical neurons in primary
culture with either Cat orMod shRNA and then analyzed cell death. As
shown in Fig. 3A, transfection with Cat or Mod shRNA, but not with
luciferase shRNA (control), was associated with a progressive loss of
GFP-positive neurons related to the incubation time. To determine
apoptotic neuronal death, the proportion of annexin V-positive/
7-AAD-negative neurons was assessed by flow cytometry within the
GFP-positive subpopulation of neurons. As depicted in Fig. 3B, the
number of GFP-positive apoptotic neurons increased progressively
when transfected with Cat or Mod shRNA, but not with luciferase
shRNA. To determine whether the apoptotic death of neurons was
specifically due to GCL subunit silencing, we next constructed cDNAs
coding for either the catalytic or modulatory GCL subunit carrying
silent third codon base point mutations within the siRNA target
FIGURE 2. The catalytic and modulatory GCL subunits are essential for glutathione
biosynthesis in intact cells. A, 24 h after transfection, specific disruption of the catalytic
or modulatory subunit by shRNA in HEK293T cells significantly decreased GCL activity
(left panel) and glutathione concentrations (right panel). B, overexpression of the cata-
lytic (but not modulatory) GCL subunit alone was sufficient to significantly increase GCL
activity (left panel) and glutathione concentrations (right panel). Concomitant overex-
pression of both subunits did not further enhance GCL activity (left panel), but synergis-
tically increased glutathione concentrations (right panel). *, p  0.05 compared with the
corresponding control values (luciferase (Luc) in A and empty vector (Empty) in B); #, p 
0.05 compared with pIRES-Cat values.
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sequence (Cat-mut orMod-mut), thus expressingmRNAs refractory to
the action of the shRNAs but having functional translational products.
As shown in Fig. 3C, the expression of Cat shRNA promoted protein
disruption of the wild-type (but not mutant) GCL subunits. Moreover,
expression of the mutant forms of both GCL subunits fully prevented
the apoptotic neuronal death triggered by the corresponding Cat or
Mod shRNA (Fig. 3D).
Neuronal Death by GCL Knockdown Is Prevented by Glutathione
Ethyl Ester or -Glutamylcysteine, but Not by Co-incubation with
Astrocytes—Previous studies have reported that glutathione concentra-
tions (36, 40) and GCL expression (41–43) in neurons increase after
co-incubation with astrocytes, and these factors may contribute to the
beneficial role of astrocytes in protection against neuronal oxidative
damage. In fact, astrocytes supply neurons with not only precursors for
the biosynthesis of glutathione (40, 44), but possibly also other antioxi-
dants such as vitamin E and ascorbate (45). In view of these observations
and with the aim of determining the putative effectiveness of GCL dis-
ruption in vivo, we investigated whether the presence of astrocytes in
co-culture altered neuronal survival upon siRNA-mediated disruption
of GCL activity. First, we observed that the site of glutathione inhibition
was exclusively exerted at the step catalyzed by GCL. Thus, both the
GCL product, -glutamylcysteine, and the membrane-permeable glu-
tathione analog glutathione ethyl ester increased neuronal glutathione
concentrations (Fig. 4A) and prevented neuronal apoptosis triggered by
specific shRNA-mediated GCL silencing (Fig. 4B). The presence of
astrocytes in co-culture increased glutathione concentrations (Fig. 5A)
in normal untransfected neurons, confirming previous results (36, 40).
However, the presence of astrocytes in co-culture did not rescue the
apoptotic neuronal death caused by shRNA-mediated catalytic ormod-
ulatory GCL subunit blockade (Fig. 5B).
Modulation of Neuronal Vulnerability to Glutamate- and Nitric
Oxide-mediated Toxicity through shRNA-mediated Inhibition or cDNA
Overexpression of GCL Subunits—A large body of evidence suggests
that glutathione deficiency enhances neuronal susceptibility to oxida-
tive and nitrosative stress (24, 42, 43, 46), reflecting the relevance of
glutathione loss for neurodegenerative diseases. However, it should be
noted that this idea was obtained only after the inhibition of pharmaco-
logical GCL activity, hence questioning any high degree of confidence in
the specificity of the effect. Here, we addressed the issue of whether
single GCL subunit silencing or overexpression would be sufficient to
modulate neuronal vulnerability to the activation of endogenous gluta-
mate receptors or to nitric oxide. Neurons pretreated with the shRNAs
targeted to GCL subunits for 24 h were further incubated with gluta-
mate (100 M for 5 min), a model that we have previously shown to
trigger activation of glutamate receptors in these cells (particularly
N-methyl-D-aspartate receptors (25)) and nitric oxide production and
neuronal death (47) via mitochondrial dysfunction (25). Glutamate
treatment was sufficient to enhance apoptotic cell death within the
GFP-negative neurons, i.e. neurons not expressing the shRNAs (Fig. 6A,
left panel). Furthermore, the time-dependent increase in apoptotic neu-
ronal death caused by glutamate treatment was synergistic with the
shRNA-mediated silencing of GCL subunits as judged by the propor-
tion of the apoptotic shRNA-expressing GFP-positive subpopulation of
neurons (Fig. 6A, right panel). It should be noted that, within this GFP-
FIGURE 3. The catalytic and modulatory GCL
subunits are essential for the survival of pri-
mary neurons. A, transfection of rat primary cor-
tical neurons with the GFP cDNA-coexpressing
pSUPER-neo/GFP vector coding for Cat or Mod
shRNA time-dependently decreased the number
of GFP-positive cells as assessed by flow cytom-
etry. B, analysis of transfected (GFP-positive) neu-
rons with annexin V and 7-AAD revealed that the
shRNA-mediated disruption of Cat or Mod was suf-
ficient to trigger a time-dependent apoptotic
(annexin V-positive/7-AAD-negative) type of cell
death. C, site-directed mutagenesis of pIRES-Cat or
pIRES-Mod with silent point mutations at the third
codon base within the shRNA target sequence
(p-IRES-Cat-mut or pIRES-Mod-mut, respectively)
resulted in the expression of proteins that were
refractory to the corresponding shRNA-mediated
protein degradation. -PFK-1, anti-phosphofruc-
tokinase-1 antibody. D, expression of the catalytic
or modulatory GCL subunit cDNA carrying silent
mutations within the shRNA target sequence
(pIRES-Cat-mut or pIRES-Mod-mut, respectively)
prevented Cat or Mod shRNA-mediated apoptotic
neuronal death. *, p  0.05 compared with the cor-
responding control values (luciferase (Luc) in A and
B and empty vector (Empty) in D).
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positive subpopulation, the considerable degree of cell death observed
in control (glutamate-untreated) shRNA Cat or Mod neurons (Fig. 6A,
right panel) was due to the silencing effect of these subunits themselves,
as reported above (Fig. 3B). Similarly, treatment with nitric oxide
enhanced apoptotic cell death within the shRNA-free GFP-negative
neurons (Fig. 6B, left panel). Furthermore, the neuronal death caused by
nitric oxide treatment was synergistic with the shRNA-mediated silenc-
ing of each GCL subunit (Fig. 6B, right panel). Finally, apoptotic neuro-
nal death due to glutamate (Fig. 7A) or nitric oxide (Fig. 7B) treatment
was prevented by overexpression of the catalytic (but not modulatory)
subunit of GCL.
DISCUSSION
Here, we have shown that independent inhibition of either the cata-
lytic or modulatory GCL subunit by the shRNA strategy elicits sponta-
neous neurodegeneration in primary cortical neurons. To our knowl-
edge, this is the first report demonstrating the absolute requirement of
both GCL subunits for neuronal survival. Knockdown of GCL subunits
leading to neuronal death was specific and selective because (i) the
expression of site-directed mutant GCL subunit cDNA constructs in
the siRNA sequence afforded cells refractory to shRNA-mediated pro-
tein degradation and apoptotic death; (ii) the exogenous addition of
products beyond the GCL step, such as -glutamylcysteine and gluta-
thione ethyl ester, fully prevented shRNA-mediated neuronal death;
and (iii) the presence of astrocytes (which supply precursors, but not
products beyond the GCL step (40, 44)) did not prevent shRNA-medi-
ated neuronal death. Together, these results suggest that shRNAagainst
either GCL subunit would be a suitable model for the intrinsic defi-
ciency of glutathione, leading to oxidative stress in cultured neurons.
Our data showing that the specific disruption of the catalytic GCL
subunit was sufficient to cause decreases in enzyme activity and gluta-
thione concentrations confirm previous work (11). In contrast, the
decrease in GCL activity and glutathione concentrations observed after
inhibition of themodulatoryGCL subunit either agrees (31) or disagrees
(32) with previous studies performed in different models. The modula-
tory subunit essentially serves to increase the affinity of the catalytic
GCL subunit for glutamate and to reduce feedback inhibition by gluta-
thione (9, 13). This is supported by our data, which show that, although
its overexpression alone did not induce any changes in GCL activity,
glutathione concentrations, or neuronal survival, its disruption did elicit
decreases in glutathione concentrations. This confirms the critical role
of the modulatory subunit in regulating GCL activity in intact cells (9,
13) and in dictating neuronal survival (this work). Moreover, disruption
of this subunit alone enhanced (as did the catalytic subunit) neuronal
susceptibility to nitric oxide, formed either endogenously by glutamate
receptor activation or exogenously by addition of a nitric oxide donor to
the cultured primary neurons. In this context, we have previously
reported that the catalyticGCL subunit can be induced by nitric oxide in
astrocytes, but not in neurons (42). Together, these data confirm the
idea that neurons are especially vulnerable to nitric oxide-mediated
mitochondrial damage and neurotoxicity (25, 26, 36) and that glutathi-
one plays an important role in neuronal survival (24). A recently
reportedwork performed in differentiated PC12 cells shows that endog-
enous nitric oxide inhibits mitochondrial complex I activity after con-
FIGURE 4. Neuronal death by GCL knockdown is prevented by glutathione ethyl
ester or -glutamylcysteine. A, incubation of rat primary cortical neurons with gluta-
thione ethyl ester (GSHee; 5 mM) or -glutamylcysteine (-GC; 5 mM) for 18 h significantly
increased intracellular glutathione concentrations. B, incubation of neurons with gluta-
thione ethyl ester or -glutamylcysteine fully prevented subsequent Cat or Mod shRNA-
mediated apoptotic neuronal death. *, p  0.05 compared with the corresponding con-
trol values (luciferase (Luc) in B). FIGURE 5. Neuronal death by GCL knockdown is not prevented by co-incubation
with astrocytes. A, incubation of rat primary cortical neurons with cell co-culture inserts
containing astrocytes () for 18 h significantly increased intracellular glutathione con-
centrations in the neurons compared with inserts not containing astrocytes (). B, incu-
bation of Cat or Mod shRNA-transfected neurons with astrocytes in co-culture did not
prevent subsequent shRNA-mediated apoptotic neuronal death. *, p  0.05 compared
with the corresponding control values ( astrocytes in A and luciferase (Luc) in B).
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comitant depletion of both the catalytic and modulatory GCL subunits
using an RNA antisense strategy (17). Here, using the more specific
siRNA strategy (18) in primary cells, we have further shown that inde-
pendent disruption of GCL subunits is sufficient to elicit neuronal
death. These results represent the first report indicating that each GCL
subunit is essential for the survival of neurons.Whether neuronal death
might be mediated by complex I inhibition (17) is a tempting specula-
tion that we were unable to explore due to the low transfection efficien-
cies obtained (7%), but it is certainly an explanation thatmerits further
investigation.
Previous studies performed in vivo have shown that targeted disrup-
tion of the catalytic GCL subunit gene in mice is lethal after embryonic
day 8 (11, 12). This is supported by our work showing that the shRNA-
mediated catalytic GCL subunit inhibition was sufficient to trigger
apoptotic neuronal death. Moreover, the inhibition of this subunit
enhanced the vulnerability of neurons to glutamate receptor activation
and nitric oxide, whereas its overexpression was markedly protective.
Together, these data unambiguously confirm the widely accepted
notion that the catalytic subunit is an essential protein for glutathione
biosynthesis and cellular viability.
In contrast, modulatory GCL subunit-targeted disruption has been
reported to yield viable and fertile mice showing mild and chronic glu-
tathione deficiency in a number of tissues (including liver, kidney, and
pancreas), erythrocytes, and blood (13); unfortunately, brain tissue was
not investigated. In this context and in light of the results demonstrating
the good viability of animals upon modulatory GCL subunit-targeted
disruption, it is intriguing that we found this to be incompatible with the
survival of primary neurons. Some redundancy in the function of the
modulatory subunit must exist in vivo (13) that is not evident in the in
vitro culture system used in our work. Although this would help to
explain the apparent discrepancy, its confirmation will require a full
examination of the brain cells of modulatory GCL subunit knockout
mice. In this context, it should be noted that, in the more in vivo-like
microenvironment (such as astrocytes in co-culture), neuronal glutathi-
one is enhanced (see Refs. 24 and 40). However, the blockade of gluta-
thione biosynthesis in neurons by themodulatory or catalytic GCL sub-
FIGURE 6. GCL knockdown enhances neuronal
vulnerability to glutamate- and nitric oxide-
mediated toxicity. Rat primary cortical neurons
were transfected with Cat or Mod shRNA; and 24 h
after transfection, cells were treated with gluta-
mate or nitric oxide as indicated. A, incubation of
neurons with glutamate (100 M for 5 min) time-
dependently enhanced the apoptotic death of
GFP-negative neurons (left panel), an effect that
was synergistic with the shRNA-mediated silenc-
ing of GCL subunits as judged by the analysis of
GFP-positive apoptotic neurons (right panel). B,
incubation of neurons with nitric oxide (1.4 M,
released from DETA/NO) enhanced the apoptotic
death of GFP-negative neurons (left panel), an
effect that was synergistic with the shRNA-medi-
ated silencing of GCL subunits as judged by the
analysis of GFP-positive apoptotic neurons (right
panel). *, p  0.05 compared with the correspond-
ing control values (not treated with glutamate or
nitric oxide); #, p  0.05 compared with luciferase
(Luc) shRNA.
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unit shRNA still promoted neuronal death despite the presence of
astrocytes. This result was expected because astrocytes do not provide
neurons with glutathione itself, but with its precursors cysteine and
glycine (in the formof cysteinylglycine) (40). In fact, exogenous addition
of the plasma membrane-permeable form of glutathione (glutathione
ethyl ester) or theGCLproduct (-glutamylcysteine) fully prevented the
neuronal death caused by GCL subunit shRNA. These data reinforce
the notion that specific targeting of the modulatory as well as catalytic
GCL subunits in neurons would be essential for their survival in vivo, at
least during the late stages of differentiation.
In conclusion, we have demonstrated that both GCL subunits are
essential for the survival of neurons. Furthermore, we have provided a
powerful and specific tool that may be useful for understanding the
mechanisms leading to neurodegeneration due to spontaneous oxida-
tive stress. In this sense, it is interesting to note that the deleterious
effects of free radicals occur during adulthood, suggesting that oxidative
stress is a critical factor in triggering aging (6, 48) as well as neurode-
generation (2, 4, 5). If so, our model of the specific and independent
disruption of GCL by the shRNA strategy might help to clarify whether
the modulation of glutathione biosynthesis in vivo is an essential factor
dictating neuronal death in neurodegenerative conditions such as Par-
kinson disease.
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